Key result
Klotho protein reduces MMP-2 activity and contractile protein release after ischemia-reperfusion injury in cardiomyocytes.
Why the study?
Ischaemia/reperfusion injury activates matrix metalloproteinases that degrade contractile proteins in cardiomyocytes, and the influence of antioxidative Klotho protein on this process needed examination.
In vitro evidence suggests that Klotho protein may act as a cardioprotective agent during ischemia/reperfusion by preventing MMP-dependent degradation of contractile proteins.
Answers are grounded in this paper and cite their sources.
Klotho may protect against cardiomyocyte ischemia/reperfusion injury in vitro; leaves open translation to in vivo or clinical settings.
Ischaemia, followed by reperfusion, causes the generation of reactive oxygen species, overproduction of peroxynitrite, activation of matrix metalloproteinases (MMPs), and subsequently the degradation of heart contractile proteins in the cardiomyocytes. Klotho is a membrane-bound or soluble protein that regulates mineral metabolism and has antioxidative activity. This study aimed to examine the influence of Klotho protein on the MMP-mediated degradation of contractile proteins during ischaemia/reperfusion injury (IRI) to the cardiomyocytes. Human cardiac myocytes (HCM) underwent in vitro chemical IRI (with sodium cyanide and deoxyglucose), with or without the administration of recombinant Klotho protein. The expression of MMP genes, the expression and activity of MMP proteins, as well as the level of contractile proteins such as myosin light chain 1 (MLC1) and troponin I (TnI) in HCM were measured. Administration of Klotho protein resulted in a decreased activity of MMP-2 and reduced the release of MLC1 and TnI that followed in cells subjected to IRI. Thus, Klotho protein contributes to the inhibition of MMP-dependent degradation of contractile proteins and prevents injury to the cardiomyocytes during IRI.
No takes yet. Share an insight, caveat, or question.
Olejnik et al. (2022) studied Ischemia/reperfusion injury. Recombinant human Klotho protein vs. Ischemia/reperfusion injury without Klotho was evaluated on MMP-2 activity and release of myosin light chain 1 (MLC1) and troponin I (TnI). Administration of Klotho protein significantly reduced the activity of MMP-2 and the subsequent release of MLC1 and TnI in human cardiomyocytes subjected to in vitro ischemia/reperfusion injury.
Synapse has enriched 10 related papers. Consider them for comparative context: